A non-inferiority trial comparing two recombinant vaccines (Hepa-B vs. Engerix-B) for hepatitis B among adults in Dhaka, Bangladesh
Authors:
Open Access
- 1 October 2021
- Vol. 39 (43) , 6385-6390
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Molecular characterization of hepatitis B virus in Bangladesh reveals a highly recombinant populationPLOS ONE, 2017
- The immunogenicity and safety of GSK’s recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experienceExpert Review of Vaccines, 2017
- Hepatitis B virus infectionThe Lancet, 2014
- Prevalence and risk factors of hepatitis B and C virus infections in an impoverished urban community in Dhaka, BangladeshBMC Infectious Diseases, 2010
- Worldwide epidemiology of HBV infection, disease burden, and vaccine preventionJournal of Clinical Virology, 2005
- Hepatology issues in Asia: Perspectives from regional leadersJournal of Gastroenterology and Hepatology, 2004
- Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memoryVaccine, 2000
- A comparison of two commercial recombinant vaccines for hepatitis B in adolescentsVaccine, 2000
- Safety and immunogenicity of hepatitis B vaccine ButaNG in adultsRevista do Instituto de Medicina Tropical de São Paulo, 1999
- Immunization Policies and Vaccine Coverage Among AdultsAnnals of Internal Medicine, 1988